A pharmacokinetic model for evaluating the impact of hepatic and intestinal first-pass loss of saquinavir in the rat

Drug Metabolism and Disposition

Volumn 39, Issue 2, 2011, Pages 294-301

  Lledo Garcia R ^a   Nacher A ^a,b   Casabo V G ^a   Merino Sanjuan M ^a,b  

^a UNIVERSITY OF VALENCIA   (Spain)

^b UNIVERSITAT POLITÈCNICA DE VALÈNCIA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

RITONAVIR; SAQUINAVIR;

ANIMAL EXPERIMENT; ARTICLE; BLOOD LEVEL; COMPETITIVE INHIBITION; CONTROLLED STUDY; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG METABOLISM; FIRST PASS EFFECT; INTESTINE; INTESTINE CELL; LIVER CELL; NONHUMAN; PERITONEAL CAVITY; POPULATION; PRECIPITATION; PRIORITY JOURNAL; RAT; SINGLE DRUG DOSE;

ADMINISTRATION, ORAL; ANIMALS; BIOLOGICAL AVAILABILITY; DRUG INTERACTIONS; HIV PROTEASE INHIBITORS; INFUSIONS, INTRAVENOUS; INJECTIONS, INTRAPERITONEAL; INJECTIONS, INTRAVENOUS; INTESTINES; LIVER; MALE; METABOLIC CLEARANCE RATE; MODELS, BIOLOGICAL; PREDICTIVE VALUE OF TESTS; RATS; RATS, WISTAR; RITONAVIR; SAQUINAVIR;

ANIMALIA; RATTUS;

EID: 79251469423     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.110.034488     Document Type: Article

References (34)

1. Amidon GL, Lennernäs H, Shah VP, and Crison JR (1995) A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res 12:413-420.
2. Beal SL and Sheiner LB (1989) NONMEM User's Guides, NONMEM Project Group, University of California, San Francisco.
3. Birnbaum L, Brown R, Bischoff K, Foran J, Blancato J, Clewell H, and Dedrick R (1994) Physiological Parameter Values for PBPK Models, International Life Science Institute, Washington, DC.
4. Bonate PL (2006) Pharmacokinetic-pharmacodynamic modeling and simulation, Springer, New York.
5. Campos Moreno E, Merino Sanjuán M, Merino V, Nácher A, Martín Algarra RV, and Casabó VG (2007) Population modelling to describe pharmacokinetics of amiodarone in rats: relevance of plasma protein and tissue depot binding. Eur J Pharm Sci 30:190-197.
6. Devine SM, Geller RB, Lin LB, Dix SP, Holland HK, Maurer D, O'Toole K, Keller J, Connaghan DG, Heffner LT, et al. (1997) The outcome of unrelated donor bone marrow transplantation in patients with hematologic malignancies using tacrolimus (FK506) and low dose methotrexate for graft-versus-host disease prophylaxis. Biol Blood Marrow Transplant 3:25-33.
7. Dickinson L, Boffito M, Back DJ, Khoo SH, Pozniak AL, Mugyenyi P, Merry C, Autar RS, Burger DM, and Aarons LJ (2008) Population pharmacokinetics of ritonavir-boosted saquinavir regimens in HIV-infected individuals. J Antimicrob Chemother 62:1344-1355.
8. Eagling VA, Back DJ, and Barry MG (1997) Differential inhibition of cytochrome P450 isoforms by the protease inhibitors, ritonavir, saquinavir and indinavir. Br J Clin Pharmacol 44:190-194.
9. Eagling VA, Wiltshire H, Whitcombe IW, and Back DJ (2002) CYP3A4-mediated hepatic metabolism of the HIV-1 protease inhibitor saquinavir in vitro. Xenobiotica 32:1-17. (Pubitemid 34095130)
10. Fitzsimmons ME and Collins JM (1997) Selective biotransformation of the human immunodeficiency virus protease inhibitor saquinavir by human small-intestinal cytochrome P4503A4: potential contribution to high first-pass metabolism. Drug Metab Dispos 25:256-266.
11. Fröhlich M, Hoffmann MM, Burhenne J, Mikus G, Weiss J, and Haefeli WE (2004) Association of the CYP3A5 A6986G (CYP3A5*3) polymorphism with saquinavir pharmacokinetics. Br J Clin Pharmacol 58:443-444.
12. Guiard-Schmid JB, Poirier JM, Meynard JL, Bonnard P, Gbadoe AH, Amiel C, Calligaris F, Abraham B, Pialoux G, Girard PM, et al. (2003) High variability of plasma drug concentrations in dual protease inhibitor regimens. Antimicrob Agents Chemother 47:986-990.
13. Hoffman C, Kamps BS, and Rocstroh JK (2007) HIV Medicine, Flying Publisher, Paris, Cagliari, Wuppertal.
14. Holladay JW, Dewey MJ, Michniak BB, Wiltshire H, Halberg DL, Weigl P, Liang Z, Halifax K, Lindup WE, and Back DJ (2001) Elevated alpha-1-acid glycoprotein reduces the volume of distribution and systemic clearance of saquinavir. Drug Metab Dispos 29:299-303.
15. Hsu A, Granneman GR, and Bertz RJ (1998) Ritonavir. Clinical pharmacokinetics and interactions with other anti-HIV agents. Clin Pharmacokinet 35:275-291.
16. Karnes HT and March C (1993) Precision, accuracy, and data acceptance criteria in biopharmaceutical analysis. Pharm Res 10:1420-1426.
17. Kupferschmidt HH, Fattinger KE, Ha HR, Follath F, and Krähenbühl S (1998) Grapefruit juice enhances the bioavailability of the HIV protease inhibitor saquinavir in man. Br J Clin Pharmacol 45:355-359.
18. Lown KS, Bailey DG, Fontana RJ, Janardan SK, Adair CH, Fortlage LA, Brown MB, Guo W, and Watkins PB (1997) Grapefruit juice increases felodipine oral availability in humans by decreasing intestinal CYP3A protein expression. J Clin Invest 99:2545-2553. (Pubitemid 27227734)
19. Lledó-García R, Nácher A, Prats-García L, Casabó VG, and Merino-Sanjuán M (2007) Bioavailability and pharmacokinetic model for ritonavir in the rat. J Pharm Sci 96:633-643.
20. Mouly SJ, Paine MF, and Watkins PB (2004) Contributions of CYP3A4, P-glycoprotein, and serum protein binding to the intestinal first-pass extraction of saquinavir. J Pharmacol Exp Ther 308:941-948.
21. Muñoz MJ, Merino-Sanjuán M, Lledó-García R, Casabó VG, Máñez-Castillejo FJ, and Nácher A (2005) Use of nonlinear mixed effect modeling for the intestinal absorption data: application to ritonavir in the rat. Eur J Pharm Biopharm 61:20-26.
22. Noble S and Faulds D (1996) Saquinavir. A review of its pharmacology and clinical potential in the management of HIV infection. Drugs 52:93-112.
23. Park S and Sinko PJ (2005) P-Glycoprotein and multidrug resistance-associated proteins limit the brain uptake of saquinavir in mice. J Pharmacol Exp Ther 312:1249-1256.
24. Plosker GL and Scott LJ (2003) Saquinavir: a review of its use in boosted regimens for treating HIV infection. Drugs 63:1299-1324.
25. Ruiz-Carretero P, Merino-Sanjuán M, Nácher A, and Casabó VG (2004) Pharmacokinetic models for the saturable absorption of cefuroxime axetil and saturable elimination of cefuroxime. Eur J Pharm Sci 21:217-223.
26. Shen DD, Kunze KL, and Thummel KE (1997) Enzyme-catalyzed processes of first-pass hepatic and intestinal drug extraction. Adv Drug Deliv Rev 27:99-127.
27. Shibata N, Gao W, Okamoto H, Kishida T, Iwasaki K, Yoshikawa Y, and Takada K (2002) Drug interactions between HIV protease inhibitors based on physiologically-based pharmacokinetic model. J Pharm Sci 91:680-689.
28. Shibata N, Kageyama M, Kishida T, Kimura K, Yoshikawa Y, Kuwahara T, Toh J, Shirasaka T, and Takada K (2003) Pharmacokinetic characterization of a human immunodeficiency virus protease inhibitor, saquinavir, during ethanol intake in rats. Biopharm Drug Dispos 24:335-344. (Pubitemid 37427996)
29. Sinko PJ, Kunta JR, Usansky HH, and Perry BA (2004) Differentiation of gut and hepatic first pass metabolism and secretion of saquinavir in ported rabbits. J Pharmacol Exp Ther 310:359-366.
30. Steimer JL, Fotteler B, Gieschke R, Wiltshire H and Buss N (1998) Predicting the Optimal Dose of Saquinavir via Modelling of Dose Exposure and Exposure-Effect Relationships. In Measurement and Kinetics of In Vivo Drug Effects, Centre for Drug Research, Amsterdam.
31. Tam-Zaman N, Tam YK, Tawfik S, and Wiltshire H (2004) Factors responsible for the variability of saquinavir absorption: studies using an instrumented dog model. Pharm Res 21:436-442.
32. U.S. Food and Drug Administration (2002) Guidance for Industry and Reviewers: Estimating the Safe Starting Dose in Clinical Trials for Therapeutics in Adult Healthy Volunteers. U.S. Department of Health and Human Services, Rockville, MD.
33. Washington CB, Wiltshire HR, Man M, Moy T, Harris SR, Worth E, Weigl P, Liang Z, Hall D, Marriott L, et al. (2000) The disposition of saquinavir in normal and P-glycoprotein deficient mice, rats, and in cultured cells. Drug Metab Dispos 28:1058-1062.
34. Williams GC and Sinko PJ (1999) Oral absorption of the HIV protease inhibitors: a current update. Adv Drug Deliv Rev 39:211-238.